Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa), a Novel Treatment for Excessive Facial Hair

    January 2000 in “ Current Medical Research and Opinion ”
    Janet G. Hickman, Ferdinand Huber, Maria Palmisano
    Studysummary This research reported that eflornithine HCl 13.9% cream generally has a favorable dermal safety profile for managing unwanted facial hair in women, though it can cause mild irritation under certain conditions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Hirsutism Journal of General Internal Medicine · 1995
    2. Ornithine Decarboxylase Activity in Relation to DNA Synthesis in Mouse Interfollicular Epidermis and Hair Follicles Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · 1975

    Related research 2

    1. Safety Evaluation of Topical Valproate Application Toxicological Research · 2013
    2. Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa), a Novel Treatment for Excessive Facial Hair Current Medical Research and Opinion · 2000